Jerry Kokoshka

At SMART Biosciences they are engaged in a coordinated effort to discover and develop novel small-molecule therapeutics to treat major age-related illnesses, including Alzheimer's disease and various forms of cancer. Since its beginning in 2005, as a spin-off of Columbia University, they have been working to address significant unmet therapeutic needs in these large and rapidly growing markets. Through its affiliation with Columbia University, SMART holds exclusive worldwide licenses to valuable intellectual property. Its scientists have identified several novel targets in two therapeutic areas that have the potential for new treatments in: Alzheimer's disease--a novel lipid target that modulates levels of neurotoxic beta-amyloid in the brain, Cancer--novel targets that modulate p53 stability, increasing tumor-cell sensitivity to cytotoxic and radiation therapies. They believe its intellectual property and scientific rationale for future compound discovery offers a compelling opportunity for commercialization. SMART is led by management and scientific advisory teams comprised of preeminent professionals distinguished in the worlds of academic science, pharmaceutical discovery, business/corporate development, finance and intellectual property law. The SMART Biosciences leadership team brings scientific rigor, business leadership, and innovation experience to its endeavors. Its discovery and development strategy employs a unique-to-the-industry collaborative network of advanced business, academic and R&D interests throughout the United States and Asia.